Private Management Group Inc. Purchases 399 Shares of Pfizer Inc. (NYSE:PFE)

Private Management Group Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,170 shares of the biopharmaceutical company’s stock after purchasing an additional 399 shares during the period. Private Management Group Inc.’s holdings in Pfizer were worth $206,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the 3rd quarter worth $30,000. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer in the 3rd quarter worth $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the 4th quarter worth $36,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock traded down $0.05 during mid-day trading on Wednesday, reaching $26.27. The company had a trading volume of 23,364,780 shares, compared to its average volume of 41,776,168. The stock’s 50-day simple moving average is $27.07 and its 200-day simple moving average is $28.52. The company has a market capitalization of $148.75 billion, a P/E ratio of 72.72, a P/E/G ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.14 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PFE. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.